MedTrace Logo

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

NCT02670824 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-08-18

No results posted yet for this study

Summary

This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single escalating dose and repeated doses of CN-105 in healthy adult participants. There will be about 48 subjects, 36 active and 12 placebo.

Conditions

  • Intracerebral Hemorrhage (ICH)

Interventions

DRUG

CN-105

Single and multiple intravenous (IV) doses of CN-105

DRUG

Placebo

Normal Saline

Sponsors & Collaborators

  • AegisCN LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670824 on ClinicalTrials.gov